On April 20, 2024, at Marina Bay Sands in Singapore, Duoc Cuu Long was honored with the “Top 50 Strong ASEAN Brands 2024” award. This accolade marks a significant milestone, acknowledging DCL’s outstanding progress over the past year.
The award is rotated annually among Southeast Asian countries, evaluated by the Asian Business Development Research Center in collaboration with various national and international organizations. It is based on international quality standards for enterprises with industry-leading brands, products, and services that are highly regarded by investors, partners, and consumers in the ASEAN market.
The “Strong ASEAN Brand 2024” announcement was made in Singapore, aiming to recognize and celebrate the contributions of businesses, encouraging them towards values of innovation, continuous improvement, and sustainable brand development. This event also promotes economic relations between Vietnam, Singapore, and the ASEAN region, enhancing trust among partners and customers in the area.
DCL excelled against stringent evaluation criteria to be recognized among the Top 50 Strong ASEAN Brands. This award acknowledges DCL’s significant strides in enhancing its competitive capabilities, progressively integrating into the international market, and affirming the trust in the high-quality products and services that DCL offers to its customers and partners.
Mr. Nghiêm Xuân Trường, Deputy General Manager of DCL, received the award.
At the ceremony, Mr. Trường stated, “The Top 50 Strong ASEAN Brands award reaffirms the trust of customers, partners, and investors in our company, and it solidifies DCL’s position and brand in the Vietnamese and Southeast Asian markets. This is a moment of joy and pride for DCL ahead of our Annual General Meeting scheduled for April 25, 2024.”
Currently, DCL operates four factories, including two pharmaceutical plants compliant with WHO GMP standards, one medical equipment manufacturing facility, and one facility producing Vicancap empty hard capsules. DCL is the only unit in Vietnam that manufactures and supplies various types of capsules. All factories operate at full capacity with advanced technology imported from Canada and South Korea.
According to the audited consolidated financial report of 2023, by the end of the year, DCL’s total assets increased from 2.105 trillion VND to over 2.277 trillion VND; shareholder equity rose from over 1.391 trillion VND to over 1.450 trillion VND. These results reflect the efforts of DCL’s leadership and all employees amidst the gloomy economic landscape of 2023.
In addition to the Top 50 Strong ASEAN Brands award, over the years, DCL has also received numerous prestigious awards such as the Second-Class Labor Medal awarded by the President of the Socialist Republic of Vietnam in 2011; the Vietnamese Medicine Star Award in 2015; and being recognized among the Top 10 Famous Brands and Labels in 2017, 2022, and 2023. These achievements are a testament to DCL’s unwavering efforts to become the most highly regarded pharmaceutical company in Vietnam by patients, partners, and employees through innovative, accessible, and excellent products and services.
